Bär & Karrer advised Swiss vehicle manufacturer Aebi Schmidt on its merger with the U.S. specialty vehicle manufacturer The Shyft Group, advised by Lenz & Staehelin. Niederer Kraft Frey advised UBS Switzerland as
Tags :Rolf Watter
Bär & Karrer has advised DSM-Firmenich on the Swiss legal aspects of the sale of the majority of its indirect stake in Robertet, a manufacturer of flavours, fragrances, and natural extracts. The transaction closed
Bär & Karrer advised UBS on the sale of its 50% stake in Swisscard. On 21 October 2024, the deal was finalized with the announcement that UBS Switzerland and American Express Swiss Holdings agreed to the sale
Ina Invest Holding, has completed a merger by absorption of its subsidiary, Ina Invest. This has resulted in an increase in its market capitalisation by around 40%. Implenia, the former co-owner of Ina Invest, was compensated
At its AGM held on 26 March 2024, SGS proposed to its shareholders, and an overwhelming majority approved, the right to receive a dividend in the form of either cash or shares of the company (scrip dividend)
AC Immune, a Swiss clinical stage biopharmaceutical company pioneering in precision medicine for neurodegenerative diseases listed on the Nasdaq completed an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per
Novartis has completed the spin-off of Sandoz‘s generics and biosimilars business, with the result that Sandoz Group debuted as an independent, publicly traded company. Sandoz shares were successfully listed on the Swiss stock exchange,
Credit Suisse and UBS signed a merger agreement, with UBS emerging as the surviving entity. With the combined market capitalization is approximately USD 65 billion, the merger follows negotiations between the two Swiss banks, prompted by
The American company Lupa Investment Holdings and the Basel based MCH Group have entered into a commitment agreement in which Lupa committed to purchase a certain number of new shares in connection with a rights
CSL Limited, a global biotechnology company based in Australia and Vifor Pharma, a Swiss-based global pharmaceutical company, entered into an agreement for CSL to launch an all-cash public tender offer to acquire all publicly held
